Reducing the risk of antibiotic-related ADRs

Fleming, Naomi

doi:10.12968/pnur.2013.24.12.602

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although both studies were retrospective, we evaluated a small cohort of 159 patients over a period of 3 years, while the comparative study evaluated a larger cohort of 1510 children over a period of 10 years. Metronidazole is a concomitant drug used by all our patients and is well known to induce nausea and vomiting in children [48,49]. Consequently, we may have over-estimated the incidence of vomiting associated with pentazocine among our cohort.…”

Section: Discussionmentioning

confidence: 98%

Off-label use of pentazocine and the associated adverse events among pediatric surgical patients in a tertiary hospital in Northern Nigeria: a retrospective chart review

Oshikoya

Ogunyinka

Godman

2019

Current Medical Research and Opinion

View full text Add to dashboard Cite

Background and aims: Pentazocine remains a widely used opioid pre-anesthetic medication and postoperative analgesic in low-and middle-income countries (LMICs) despite concerns. We assessed the adverse events (AEs) associated with off-label use of pentazocine in pediatric surgical patients and determined the possible risk factors associated with slow respiratory AEs. Method: Children ≤ 18 years old for surgery administered pentazocine IM/IV as a pre-anesthetic medication or post-operative analgesic. Pertinent data including total daily dose and duration of use of pentazocine and its associated AEs were obtained from patients' case files. Risk factors associated with slow respiratory AEs were determined using logistic regression analyses. Results: 159 patients were included with median age of 2 years and mainly males (52.8%). Pentazocine was administered off-label to all patients for post-operative pain management (96.2%) or pre-anesthetic medication (3.8%). All patients experienced at least one AE with most experiencing 2-7 AEs. Rapid breathing (116; 18.4%), followed by sleepiness/sedation/drowsiness (90; 14.3%) and fast pulse (79; 12.5%) was the most frequently reported AEs. None of the demographics and clinical variables significantly predicted the risk of slow respiratory AEs. Conclusion: Off-label use of pentazocine is common and associated with multiple AEs. Care is needed as no predictors of slow respiratory AEs were observed.

show abstract

Section: Discussionmentioning

confidence: 98%